Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>

Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2025-05-12 Sale | 2025-05-13 5:05 pm | GENELUX Corp | GNLX | Ryder Sean General Counsel | 4,475 | $2.92 | $13,067 | 47,621 (Direct) | View |
2025-05-12 Sale | 2025-05-13 5:05 pm | GENELUX Corp | GNLX | Zindrick Thomas President and CEO | 10,764 | $2.92 | $31,431 | 191,447 (Direct) | View |
2025-05-12 Sale | 2025-05-13 5:05 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 5,579 | $2.92 | $16,291 | 47,640 (Direct) | View |
2025-05-12 Sale | 2025-05-13 5:05 pm | GENELUX Corp | GNLX | Cappello Joseph VP, Pharmaceutical Development | 4,737 | $2.92 | $13,832 | 52,266 (Direct) | View |
2025-05-12 Sale | 2025-05-13 5:05 pm | GENELUX Corp | GNLX | Smalling Ralph Head of Regulatory | 1,259 | $2.92 | $3,676 | 34,760 (Direct) | View |
2024-12-30 Sale | 2024-12-30 7:48 pm | GENELUX Corp | GNLX | Tyree James L Director | 3,460 | $2.46 | $8,512 | 45,791 (Direct) | View |
2024-12-16 Sale | 2024-12-18 4:35 pm | GENELUX Corp | GNLX | Zindrick Thomas President and CEO | 14,315 | $2.34 | $33,497 | 37,372 (Direct) | View |
2024-12-16 Sale | 2024-12-18 4:35 pm | GENELUX Corp | GNLX | Zak Lourie S. Chief Financial Officer | 2,103 | $2.34 | $4,921 | 40,802 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2025-09-01 Option Award | 2025-09-03 4:15 pm | N/A 2027-09-18 | GENELUX Corp | GNLX | Zindrick Thomas President and CEO | 1,355,940 | $0 | 1,355,940 (Direct) | View |
2025-09-01 Option Award | 2025-09-03 4:15 pm | N/A 2029-09-20 | GENELUX Corp | GNLX | Yu Yong SVP, Clinical Development | 272,652 | $0 | 272,652 (Direct) | View |
2025-09-01 Option Award | 2025-09-03 4:15 pm | N/A 2030-09-23 | GENELUX Corp | GNLX | Smalling Ralph Head of Regulatory | 18,333 | $0 | 79,323 (Direct) | View |
2025-09-01 Option Award | 2025-09-03 4:15 pm | N/A 2026-12-30 | GENELUX Corp | GNLX | Cappello Joseph Chief Technical Officer | 174,999 | $0 | 174,999 (Direct) | View |
2025-08-27 Option Award | 2025-08-29 4:30 pm | N/A 2035-08-26 | GENELUX Corp | GNLX | Thomas John Director | 50,859 | $0 | 531,360 (Direct) | View |
2025-08-27 Option Award | 2025-08-29 4:30 pm | N/A 2035-08-26 | GENELUX Corp | GNLX | Zindrick Thomas President and CEO | 840,000 | $0 | 1,032,961 (Direct) | View |
2025-08-27 Option Award | 2025-08-29 4:30 pm | N/A 2035-08-26 | GENELUX Corp | GNLX | Smalling Ralph Head of Regulatory | 61,000 | $0 | 95,760 (Direct) | View |
2025-08-27 Option Award | 2025-08-29 4:30 pm | N/A 2035-08-26 | GENELUX Corp | GNLX | Smither John W Director | 50,859 | $0 | 103,570 (Direct) | View |
2025-08-27 Option Award | 2025-08-29 4:30 pm | N/A 2035-08-26 | GENELUX Corp | GNLX | Yu Yong SVP, Clinical Development | 236,000 | $0 | 284,556 (Direct) | View |
2025-08-27 Option Award | 2025-08-29 4:30 pm | N/A 2035-08-26 | GENELUX Corp | GNLX | Mirabelli Mary Director | 50,859 | $0 | 101,860 (Direct) | View |
2025-08-27 Option Award | 2025-08-29 4:30 pm | N/A 2035-08-26 | GENELUX Corp | GNLX | Tyree James L Director | 50,859 | $0 | 96,650 (Direct) | View |
2025-08-27 Option Award | 2025-08-29 4:30 pm | N/A 2035-08-26 | GENELUX Corp | GNLX | Cappello Joseph Chief Technical Officer | 250,000 | $0 | 302,266 (Direct) | View |
2025-07-01 Option Award | 2025-07-02 4:16 pm | N/A 2035-06-30 | GENELUX Corp | GNLX | Groen Eric General Counsel & Secretary | 270,000 | $0 | 270,000 (Direct) | View |
2025-06-06 Gift | 2025-06-24 4:10 pm | N/A N/A | GENELUX Corp | GNLX | Thomas John Director | 25,000 | $0 | 480,501 (Direct) | View |
2025-03-14 Option Award | 2025-04-17 4:58 pm | N/A N/A | GENELUX Corp | GNLX | Smalling Ralph Head of Regulatory | 4,172 | $0 | 36,019 (Direct) | View |
2025-03-14 Option Award | 2025-04-17 4:57 pm | N/A N/A | GENELUX Corp | GNLX | Cappello Joseph VP, Pharmaceutical Development | 13,350 | $0 | 57,003 (Direct) | View |
2025-03-14 Option Award | 2025-04-17 4:56 pm | N/A N/A | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 13,350 | $0 | 53,219 (Direct) | View |
2025-03-14 Option Award | 2025-04-17 4:55 pm | N/A N/A | GENELUX Corp | GNLX | Ryder Sean General Counsel | 10,708 | $0 | 52,096 (Direct) | View |
2025-03-14 Option Award | 2025-04-17 4:54 pm | N/A N/A | GENELUX Corp | GNLX | Zindrick Thomas President and CEO | 30,339 | $0 | 202,211 (Direct) | View |
2025-01-31 Option Award | 2025-02-03 6:16 pm | N/A 2035-01-30 | GENELUX Corp | GNLX | Pulisic Matthew Chief Financial Officer | 275,000 | $0 | 275,000 (Direct) | View |
2024-08-01 Option Award(A) | 2024-12-31 1:20 pm | N/A 2034-07-31 | GENELUX Corp | GNLX | Thomas John Director | 50,469 | $0 | 50,469 (Direct) | View |
2024-08-01 Option Award(A) | 2024-12-31 1:20 pm | N/A 2034-07-31 | GENELUX Corp | GNLX | Mirabelli Mary Director | 50,469 | $0 | 50,469 (Direct) | View |
2024-08-01 Option Award(A) | 2024-12-31 1:20 pm | N/A 2034-07-31 | GENELUX Corp | GNLX | Smither John W Director | 50,469 | $0 | 50,469 (Direct) | View |
2024-08-01 Option Award(A) | 2024-12-31 1:20 pm | N/A 2034-07-31 | GENELUX Corp | GNLX | Tyree James L Director | 50,469 | $0 | 50,469 (Direct) | View |
2024-12-18 Option Award | 2024-12-20 8:49 pm | N/A 2034-12-17 | GENELUX Corp | GNLX | Smalling Ralph Head of Regulatory | 36,625 | $0 | 52,947 (Direct) | View |
2024-12-18 Option Award | 2024-12-20 8:48 pm | N/A 2034-12-17 | GENELUX Corp | GNLX | Ryder Sean General Counsel | 52,000 | $0 | 71,388 (Direct) | View |
2024-12-18 Option Award | 2024-12-20 8:46 pm | N/A 2034-12-17 | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 68,000 | $0 | 78,869 (Direct) | View |
2024-12-18 Option Award | 2024-12-20 8:45 pm | N/A 2034-12-17 | GENELUX Corp | GNLX | Cappello Joseph VP, Pharmaceutical Development | 68,000 | $0 | 82,653 (Direct) | View |
2024-12-18 Option Award | 2024-12-20 8:44 pm | N/A 2034-12-17 | GENELUX Corp | GNLX | Zak Lourie S. Chief Financial Officer | 98,175 | $0 | 138,977 (Direct) | View |
2024-12-18 Option Award | 2024-12-20 8:43 pm | N/A 2034-12-17 | GENELUX Corp | GNLX | Zindrick Thomas President and CEO | 317,500 | $0 | 354,872 (Direct) | View |